12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vorapaxar regulatory update

Merck announced plans to file regulatory applications in the U.S. and EU next year for vorapaxar to prevent cardiovascular events in a more restricted patient population than the 1 originally pursued in Phase III trials. Merck plans to seek an indication in patients with a history of heart attack but no history of transient ischemic attack or stroke. Vorapaxar is a protease-activated receptor 1...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >